Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Studies show adverse effects of tamoxifen as early breast cancer therapy
December 29th, 2005
The latest data for the early breast cancer treatment Arimidex (anastrozole), have shown some potentially serious adverse consequences postmenopausal women may face if they are initially prescribed tamoxifen rather than an optimal hormonal treatment following surgery to remove a tumor. The criticalness of this initial treatment decision was emphasized in a number of new data presentations at ECCO 13, The European Cancer Conference in Paris, France. The latest data have confirmed that women are placed at an increased risk of their cancer coming back if they are prescribed tamoxifen, the previous standard treatment, instead of anastrozole. This risk is...
Source: Women's Health Weekly (2005-12-29)
|
